Return to homepagePandemic Pact

EBO-PEP : Evaluation of the efficacy of a post-exposure prophylaxis (PEP) strategy in contacts at risk of developing a Filovirus Disease: an adaptive platform trial

  • Funded by Agence nationale de recherche sur le sida et les hépatites virale [National Agency for AIDS Research] (ANRS)
  • Total publications:0 publications

Grant number: ANRS0515s

Grant search

Key facts

  • Disease

    Ebola

  • Start & end year

    2021
    2026

  • Known Financial Commitments (USD)

    $1,175,000

  • Funder

    Agence nationale de recherche sur le sida et les hépatites virale [National Agency for AIDS Research] (ANRS)

  • Principal Investigator

    JASPARD Marie, MBALA Placide

  • Research Location

    Congo (DRC)

  • Lead Research Institution

    Service des maladies infectieuses et tropicale, Inserm UMR-1136 IPLESP Hôpital Saint-Antoine, Paris, France

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older), Children (1 year to 12 years)

  • Vulnerable Population

    Pregnant women, Other

  • Occupations of Interest

    Unspecified

Abstract

The EBO-PEP platform trial, which has been in preparation since 2024, aims to assess the efficacy of various drugs used as a post-exposure prophylaxis (PEP) strategy among high-risk contacts of filovirus disease - a family of viruses that includes the Bundibugyo virus - in various countries in Sub-Saharan Africa (DRC, Uganda, Guinea, Liberia, Sierra Leone). Its first implementation (or 'sub-protocol') focuses on evaluating obeldesivir as PEP against the Bundibugyo virus in the DRC and Uganda. A second sub-protocol is also planned to administer, on a compassionate use basis, another antiviral drug, remdesivir, to children under 12 and pregnant or breastfeeding women who have had high-risk contact. This is because the available data on obeldesivir in these specific populations are insufficient to permit its use.